Review article

Helicobacter pylori and gastric adenocarcinoma

W. L. Peterson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Gastric adenocarcinoma is still the second most common cause of death from cancer, even though it is on the decline in developed countries. Although H. pylori gastritis appears to be a necessary antecedent to the development of gastric adenocarcinoma, it is not a sufficient factor in and of itself. Other required factors for the progression of this disease are poorly understood. Patients with antral predominant gastritis seem protected from the disease, while patients with pangastritis are predisposed to both diffuse- and intestinal-type adenocarcinoma. Development of a vaccine against H. pylori might yield promising results in decreasing the incidence of gastric adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)40-46
Number of pages7
JournalAlimentary Pharmacology and Therapeutics, Supplement
Volume16
Issue number1
StatePublished - Mar 2002

Fingerprint

Helicobacter pylori
Stomach
Adenocarcinoma
Gastritis
Developed Countries
Disease Progression
Cause of Death
Vaccines
Incidence
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Review article : Helicobacter pylori and gastric adenocarcinoma. / Peterson, W. L.

In: Alimentary Pharmacology and Therapeutics, Supplement, Vol. 16, No. 1, 03.2002, p. 40-46.

Research output: Contribution to journalArticle

@article{6a9bd433a0f74a7c8bc1f78952922698,
title = "Review article: Helicobacter pylori and gastric adenocarcinoma",
abstract = "Gastric adenocarcinoma is still the second most common cause of death from cancer, even though it is on the decline in developed countries. Although H. pylori gastritis appears to be a necessary antecedent to the development of gastric adenocarcinoma, it is not a sufficient factor in and of itself. Other required factors for the progression of this disease are poorly understood. Patients with antral predominant gastritis seem protected from the disease, while patients with pangastritis are predisposed to both diffuse- and intestinal-type adenocarcinoma. Development of a vaccine against H. pylori might yield promising results in decreasing the incidence of gastric adenocarcinoma.",
author = "Peterson, {W. L.}",
year = "2002",
month = "3",
language = "English (US)",
volume = "16",
pages = "40--46",
journal = "Alimentary Pharmacology and Therapeutics, Supplement",
issn = "0953-0673",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Review article

T2 - Helicobacter pylori and gastric adenocarcinoma

AU - Peterson, W. L.

PY - 2002/3

Y1 - 2002/3

N2 - Gastric adenocarcinoma is still the second most common cause of death from cancer, even though it is on the decline in developed countries. Although H. pylori gastritis appears to be a necessary antecedent to the development of gastric adenocarcinoma, it is not a sufficient factor in and of itself. Other required factors for the progression of this disease are poorly understood. Patients with antral predominant gastritis seem protected from the disease, while patients with pangastritis are predisposed to both diffuse- and intestinal-type adenocarcinoma. Development of a vaccine against H. pylori might yield promising results in decreasing the incidence of gastric adenocarcinoma.

AB - Gastric adenocarcinoma is still the second most common cause of death from cancer, even though it is on the decline in developed countries. Although H. pylori gastritis appears to be a necessary antecedent to the development of gastric adenocarcinoma, it is not a sufficient factor in and of itself. Other required factors for the progression of this disease are poorly understood. Patients with antral predominant gastritis seem protected from the disease, while patients with pangastritis are predisposed to both diffuse- and intestinal-type adenocarcinoma. Development of a vaccine against H. pylori might yield promising results in decreasing the incidence of gastric adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0036515656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036515656&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 40

EP - 46

JO - Alimentary Pharmacology and Therapeutics, Supplement

JF - Alimentary Pharmacology and Therapeutics, Supplement

SN - 0953-0673

IS - 1

ER -